# Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

> **NCT03075553** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 12 (actual)

## Conditions studied

- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Hepatosplenic T-Cell Lymphoma
- HTLV-1 Infection
- NK-Cell Lymphoma, Unclassifiable
- Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Mycosis Fungoides
- Refractory Adult T-Cell Leukemia/Lymphoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-cell Lymphoma
- Refractory Enteropathy-Associated T-Cell Lymphoma
- Refractory Mycosis Fungoides
- Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03075553
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-17
- **Primary completion:** 2019-05-29
- **Final completion:** 2019-05-29
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** due to poor response
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03075553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03075553, "Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03075553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*